-
Case Sharing Prof. Li Chen: Can Serinisol in the Treatment of Plasmablastic Lymphoma Reverse the Outcomes of Multidrug-Refractory Patients?
Time of Update: 2022-02-22
Plasmablastic lymphoma (PBL) is a rare and aggressive subtype of non-Hodgkin's lymphoma (NHL), due to its special morphological and immunophenotypic features, chemotherapy resistance, and clinical features with a high recurrence rate , treatment is extremely challenging and the patient's overall prognosis is poor .
-
Prof. He Xuhua: Application of Precise Diagnosis in Hematological Tumor Treatment The 2nd China Hematology Development Conference
Time of Update: 2022-02-22
Hosted by the Chinese Academy of Medical Sciences and Peking Union Medical College, and organized by the Hematology Hospital of the Chinese Academy of Medical Sciences and the National Clinical Resea
-
After veneclax + azacitidine becomes the standard treatment for unfit AML, how is the clinical value of MRD reflected?
Time of Update: 2022-02-21
The phase III VIALE-A study established veneclava combined with azacitidine as a new standard of care for elderly AML patients who are not suitable for intensive chemotherapy and composite complete remission (CRc; complete remission [CR] + complete remission with incomplete hematologic recovery [CRi]) rates, compared with azacitidine alone, veneclax plus azacitidine group was negative for CRc+MRD The rate was higher (23.
-
"Safety Investigators" Look at the B Domain of Coagulation Factor VIII
Time of Update: 2022-02-21
Investigative clue 1 - Deletion of FVIII in B region may increase immune risk and has a shorter half-life The heavy chain consists of a truncated B domain encoding 21 amino acids of the native B domain and a light chain (Figure 2) 5 .
-
[Fast News] The first live broadcast of the "Precision Medicine" series ended successfully, and a number of big coffee experts talked about the application of MRD in the field of hematological tumors!
Time of Update: 2022-02-21
Yu Yiling, Director of BeiGene's Clinical Biomarkers Department, expressed his unique insights on the "application of MRD in the research and development of new hematological tumors" .
-
The company founded by Professor Rao Yi chose hemophilia A, and another AAV gene therapy passed the approval of Yimai Meng
Time of Update: 2022-02-20
AAV Gene Therapy ➤ BioMarin's valoctocogene roxaparvovec (valrox) In January 2022, the company announced full data from the Phase 3 clinical study GENEr8-1 of valrox, with 134 subjects achieving all primary and secondary outcomes in the two-year analysis To the efficacy endpoint .
-
Professor Han Yue: Advances in the treatment of thrombocytopenia after hematopoietic stem cell transplantation The 2nd China Hematology Development Conference
Time of Update: 2022-02-20
Professor Han Yue said that post-transplant hemorrhage greatly affects the prognosis of patients, and its risk factors include: graft-versus-host disease (GVHD), infection, thrombocytopenia, use of anticoagulant drugs, endothelial cell damage, etc.
-
Nat Med: Long-term outcomes of lentiviral gene therapy for beta-hemoglobinopathies
Time of Update: 2022-02-19
HGB-205 is a Phase 1/2, open-label, single-arm, non-randomized intervention study with a duration of 2 years, conducted at a single center, followed by observation of LTF-303 (NCT02633943) and LTF-307 (NCT02633943) and LTF-307 ( NCT04628585) for transfusion-dependent β-thalassemia and sickle cell disease, respectively .
-
Special discussion on clinical research progress of hematopoietic stem cell transplantation in patients with severe aplastic anemia
Time of Update: 2022-02-19
Some studies have selected early MUD-HSCT in pediatric patients, and the survival rate is 90%, which is comparable to the results of HLA-matched sibling donor transplantation [6] .
-
Hematology: Patient vital signs associated with ICU admission for acute leukemia: a retrospective chart review.
Time of Update: 2022-02-18
Figure 5: Changes in vital signs over time: Fractional inspired oxygen (FiO 2 ) (A) and respiratory rate (RR) (B) showed a significant increase from baseline within the 24 hours prior to ICU admission in the intensive care unit (ICU) group .
-
J Thromb Haemost: Platelet-derived microvesicle levels are associated with venous thromboembolism risk
Time of Update: 2022-02-18
In a population-based nested case-control study of 314 VTE cases and 705 age- and sex-matched controls (from the Tromsø study), we analyzed the proportion (%) of PD microvesicles in plasma compared with Associations between the risk of future venous thromboembolic events .
-
Pseudo-thrombocytopenia dependent on EDTA-K2 and sodium citrate at the same time, have you seen it?
Time of Update: 2022-02-18
Regis stainingFor EDTA-PTCP patients, our current main treatment method is to re-collect a tube of sodium citrate anticoagulation for testing, and multiply the platelet test result by 1.
-
Regarding the three items of anemia, the key points are here!
Time of Update: 2022-02-18
Folic acid deficiency and macrocytic anemia The lack of folic acid inhibits the synthesis of erythrocyte DNA, the formation of nucleoprotein is insufficient, the newly formed erythrocytes in the bone marrow cannot mature, the cell division and proliferation rate decreases, and the cell volume increases, resulting in the appearance of giant erythrocytes .
-
How to diagnose lymphoblastic acute leukemia
Time of Update: 2022-02-18
The FAB Collaborative Group clearly pointed out that M0 cannot be diagnosed based on morphology, and its main characteristics are:Bone marrow blasts ≥30% (NEC), with mostly clear or moderately basophilic cytoplasm, no azurophilic granules and Auer bodies, and obvious nucleoli, similar to ALL-L2 type .
-
Support Care Cancer: Thrombosis and catheter-related bloodstream infections are significant complications of CVC in AML patients
Time of Update: 2022-02-18
A research team conducted a prospective observational study to assess complications associated with CVC use during induction chemotherapy in adult AML patients and to assess patient-reported quality of life outcomes during and after hospitalization .
-
How can liver cysts and hemangiomas be differentiated based on plain MRI scans alone?
Time of Update: 2022-02-18
Clinically, many abnormal signals are often found after plain MRI of liver, the most common ones are cysts and hemangioma , both of which show long T1 and long T2 signals, which need to be differentiated by enhanced scanning .
-
AIDS: Long-term effects of iloyoumab in patients with HIV and dyslipidemia
Time of Update: 2022-02-17
To assess the safety and efficacy of ilotinib in people living with HIV, investigators conducted a multinational, placebo-controlled, double-blind, randomized, phase 3 clinical trial analyzing the open-label (OLP) period , the effect of monthly subcutaneous injection of ilovolumab 420 mg on LDL-C levels after 24 weeks in HIV carriers with hypercholesterolemia/mixed dyslipidemia, and statistical emergent adverse events (TEAEs) .
-
Why should the blood clot specimen be centrifuged for 15 minutes?
Time of Update: 2022-02-16
” The requirements for the reagents and equipment of APTT in Chapter 4, Section 5 "Testing of Coagulation Factors" : " Use 109mmol /L sodium citrate solution as 1:9 anticoagulation, centrifuge at 3000r/min for 10 minutes, and obtain platelet-poor plasma.
-
Acta Oncol: Long-term follow-up of first-line dasatinib in elderly chronic-phase chronic myeloid leukemia patients treated outside of clinical trials: a real-life cohort observational study
Time of Update: 2022-02-16
Despite these outstanding results, there are limited data in chronic-phase chronic myeloid leukemia (CP-CML) patients >75 years of age receiving first-line second-generation tyrosine kinase inhibitor therapy .
-
Daratumumab may be an effective maintenance strategy after ASCT in NDMM patients
Time of Update: 2022-01-27
RESULTS: Study process and patient characteristics Between May 30, 2016, and June 18, 2018, 886 patients who achieved ≥ partial response (PR) in Part 1 were randomly assigned to daratumumab maintenance therapy ( 442 cases) or observation group (444 cases) (Figure 1) .
